Neurocrine Biosciences Total Liabilities 2010-2024 | NBIX

Neurocrine Biosciences total liabilities for the quarter ending June 30, 2024 were $0.796B, a 4.7% increase year-over-year.

  • Neurocrine Biosciences total liabilities for 2023 were $1.019B, a 54.24% increase from 2022.
  • Neurocrine Biosciences total liabilities for 2022 were $0.661B, a 5.38% decline from 2021.
  • Neurocrine Biosciences total liabilities for 2021 were $0.699B, a 14.79% increase from 2020.

Neurocrine Biosciences Total Liabilities 2010-2024 | NBIX

  • Neurocrine Biosciences total liabilities for 2023 were $1.019B, a 54.24% increase from 2022.
  • Neurocrine Biosciences total liabilities for 2022 were $0.661B, a 5.38% decline from 2021.
  • Neurocrine Biosciences total liabilities for 2021 were $0.699B, a 14.79% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.7B
Takeda Pharmaceutical (TAK)$47.3B
Merck (MKGAF)$23.7B
Astellas Pharma (ALPMY)$21.5B
Summit Therapeutics (SMMT)$19B
Sandoz Group AG (SDZNY)$17.5B
United Therapeutics (UTHR)$15.4B
Shionogi (SGIOY)$13.3B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6.1B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Crinetics Pharmaceuticals (CRNX)$4.2B
Corcept Therapeutics (CORT)$4.1B
Dyne Therapeutics (DYN)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
PTC Therapeutics (PTCT)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.5B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.5B
Cassava Sciences (SAVA)$1.5B
Ardelyx (ARDX)$1.4B